- Home
- SANA vs BBNX Comparison
SANA vs BBNX Comparison
Compare SANA & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SANA | BBNX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SANA | BBNX |
|---|---|---|
| Price | $4.75 | $14.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $7.83 | ★ $29.08 |
| AVG Volume (30 Days) | ★ 2.6M | 1.4M |
| Earning Date | 03-16-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,570,000.00 |
| Revenue This Year | N/A | $53.58 |
| Revenue Next Year | N/A | $35.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.01 |
| 52 Week Low | $1.26 | $8.89 |
| 52 Week High | $6.55 | $32.71 |
Technical Indicators
Market Signals| Indicator | SANA | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 23.67 |
| Support Level | $4.61 | $14.46 |
| Resistance Level | $5.20 | $19.03 |
| Average True Range (ATR) | 0.32 | 1.65 |
| MACD | 0.03 | -0.59 |
| Stochastic Oscillator | 51.00 | 1.52 |
Price Performance
Historical ComparisonAbout SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.